Max B Albers1, Damiano Librizzi2, Caroline L Lopez3, Jerena Manoharan3, Jonas C Apitzsch4, Emily P Slater3, Carmen Bollmann3, Peter H Kann5, Detlef K Bartsch3. 1. Department of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, Marburg, Germany. max.b.albers@gmail.com. 2. Department of Nuclear Medicine, University Hospital of Giessen and Marburg, Philipps University of Marburg, Marburg, Germany. 3. Department of Visceral, Thoracic and Vascular Surgery, University Hospital of Giessen and Marburg, Philipps University of Marburg, Marburg, Germany. 4. Department of Diagnostic and Interventional Radiology, University Hospital of Giessen and Marburg, Philipps University of Marburg, Marburg, Germany. 5. Division of Endocrinology, University Hospital of Giessen and Marburg, Philipps University of Marburg, Marburg, Germany.
Abstract
BACKGROUND: Routine screening is recommended for patients with multiple endocrine neoplasia type 1 (MEN1) to enable early detection and treatment of associated neuroendocrine neoplasms (NEN). Gallium68-DOTATOC-Positron emission tomography combined with computed tomography (Ga-68-DOTATOC-PET-CT) is a very sensitive and specific imaging technique for the detection of sporadic neuroendocrine tumors. The present study evaluated the value of Ga-68-DOTATOC-PET-CT in routine screening of patients with MEN1. METHODS: Between January 2014 and March 2016, all MEN1 patients underwent Ga-68-DOTATOC-PET-CT in addition to conventional imaging (computed tomography of the thorax, magnetic resonance imaging of the abdomen and pituitary, endoscopic ultrasonography). The diagnostic yield of conventional imaging and Ga-68-DOTATOC-PET-CT was prospectively documented and compared, and treatment changes caused by the addition of Ga-68-DOTATOC-PET-CT were recorded. RESULTS: Conventional imaging detected 145 NENs, mainly pancreaticoduodenal NENs (n = 117, 81%), in 31 of 33 MEN1 patients. Ga-68-DOTATOC-PET-CT detected 55 NENs in 23 of the 33 patients (p = 0.0001). Ninety (62%) NENs detected by conventional imaging were missed by DOTATOC-PET-CT. The majority of missed lesions were pNEN (n = 68; 74%). The sensitivity of Ga-68-DOTATOC-PET-CT for NENs <5, 5-9, 10-19 and ≥20 mm was 0, 29, 81 and 100%, respectively. However, Ga-68-DOTATOC-PET-CT detected more liver and lymph node metastases in patients with known metastatic disease, which did not lead to a change of patients' management. In one patient (3%), Ga-68-DOTATOC-PET-CT was the only imaging modality that detected a small intestine NEN and led to potentially curative surgery. CONCLUSION: Ga-68-DOTATOC-PET-CT cannot be recommended for routine screening of MEN1 patients. It might provide important additional information in patients with suspected or known metastatic disease.
BACKGROUND: Routine screening is recommended for patients with multiple endocrine neoplasia type 1 (MEN1) to enable early detection and treatment of associated neuroendocrine neoplasms (NEN). Gallium68-DOTATOC-Positron emission tomography combined with computed tomography (Ga-68-DOTATOC-PET-CT) is a very sensitive and specific imaging technique for the detection of sporadic neuroendocrine tumors. The present study evaluated the value of Ga-68-DOTATOC-PET-CT in routine screening of patients with MEN1. METHODS: Between January 2014 and March 2016, all MEN1patients underwent Ga-68-DOTATOC-PET-CT in addition to conventional imaging (computed tomography of the thorax, magnetic resonance imaging of the abdomen and pituitary, endoscopic ultrasonography). The diagnostic yield of conventional imaging and Ga-68-DOTATOC-PET-CT was prospectively documented and compared, and treatment changes caused by the addition of Ga-68-DOTATOC-PET-CT were recorded. RESULTS: Conventional imaging detected 145 NENs, mainly pancreaticoduodenal NENs (n = 117, 81%), in 31 of 33 MEN1patients. Ga-68-DOTATOC-PET-CT detected 55 NENs in 23 of the 33 patients (p = 0.0001). Ninety (62%) NENs detected by conventional imaging were missed by DOTATOC-PET-CT. The majority of missed lesions were pNEN (n = 68; 74%). The sensitivity of Ga-68-DOTATOC-PET-CT for NENs <5, 5-9, 10-19 and ≥20 mm was 0, 29, 81 and 100%, respectively. However, Ga-68-DOTATOC-PET-CT detected more liver and lymph node metastases in patients with known metastatic disease, which did not lead to a change of patients' management. In one patient (3%), Ga-68-DOTATOC-PET-CT was the only imaging modality that detected a small intestine NEN and led to potentially curative surgery. CONCLUSION:Ga-68-DOTATOC-PET-CT cannot be recommended for routine screening of MEN1patients. It might provide important additional information in patients with suspected or known metastatic disease.
Authors: Aaron I Vinik; Eugene A Woltering; Richard R P Warner; Martyn Caplin; Thomas M O'Dorisio; Gregory A Wiseman; Domenico Coppola; Vay Liang W Go Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: A Kroiss; D Putzer; C Decristoforo; C Uprimny; B Warwitz; B Nilica; M Gabriel; D Kendler; D Waitz; G Widmann; I J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2013-01-05 Impact factor: 9.236
Authors: Samira M Sadowski; Corina Millo; Candice Cottle-Delisle; Roxanne Merkel; Lily A Yang; Peter Herscovitch; Karel Pacak; William F Simonds; Stephen J Marx; Electron Kebebew Journal: J Am Coll Surg Date: 2015-04-20 Impact factor: 6.113
Authors: Jens Waldmann; Volker Fendrich; Nils Habbe; Detlef K Bartsch; Emily P Slater; Peter H Kann; Matthias Rothmund; Peter Langer Journal: World J Surg Date: 2009-06 Impact factor: 3.352
Authors: Dirk-Jan van Beek; Helena M Verkooijen; Sjoerd Nell; Bert A Bonsing; Casper H van Eijck; Harry van Goor; Frederik J H Hoogwater; Elisabeth J M Nieveen van Dijkum; Geert Kazemier; Cornelis H C Dejong; Lodewijk A A Brosens; Frank J Wessels; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens Journal: Neuroendocrinology Date: 2020-07-28 Impact factor: 4.914
Authors: Alexander Appelstrand; Fredrik Bergstedt; Anna-Karin Elf; Henrik Fagman; Per Hedenström Journal: Sci Rep Date: 2022-04-08 Impact factor: 4.379
Authors: Daniel J Cuthbertson; Jorge Barriuso; Angela Lamarca; Prakash Manoharan; Thomas Westwood; Matthew Jaffa; Stephen W Fenwick; Christina Nuttall; Fiona Lalloo; Andreas Prachalias; Michail Pizanias; Hulya Wieshmann; Mairead G McNamara; Richard Hubner; Raj Srirajaskanthan; Gillian Vivian; John Ramage; Martin O Weickert; D Mark Pritchard; Sobhan Vinjamuri; Juan Valle; Vincent S Yip Journal: Front Endocrinol (Lausanne) Date: 2021-06-07 Impact factor: 5.555